Skip to content

Biogen BIIB Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin75.5%-0.2pp75.7%+0.5pp75.2%-0.2pp75.4%-0.1pp75.6%-0.5pp
Net margin14.3%+0.7pp13.6%-2.4pp16%+0.7pp15.3%+0.2pp15.1%-1.8pp
EBITDA margin27%+0.8pp26.2%-2.3pp28.5%+1.1pp27.4%+0.4pp26.9%-1.7pp
Free cash flow margin24.4%+3.6pp20.7%-2.2pp22.9%+3.1pp19.8%-5.0pp24.8%-3.3pp
Returns
Return on equity8%+0.3pp7.7%-1.6pp9.3%+0.2pp9.1%-0.1pp9.2%-1.2pp
Return on assets4.9%+0.3pp4.7%-0.9pp5.6%0.0pp5.6%+0.1pp5.4%-0.5pp
Return on invested capital7.8%+0.8pp7%-1.8pp8.8%+0.7pp8%-0.1pp8.1%-0.4pp
Efficiency
Asset turnover0.3×0.0×0.3×0.0×0.4×0.0×0.4×0.0×0.4×0.0×
Inventory turnover19×-1.1×20.1×+0.7×19.4×+0.7×18.8×-3.8×22.6×-3.7×
Liquidity
Current ratio3.1×+0.4×2.7×0.0×2.7×+0.2×2.5×+1.1×1.4×+0.1×
Quick ratio+0.4×2.6×0.0×2.7×+0.2×2.5×+1.0×1.4×+0.1×
Cash ratio1.1×+0.2×0.9×-0.3×1.2×+0.3×0.9×+0.4×0.5×+0.1×
Leverage
Debt-to-equity0.4×0.0×0.4×0.0×0.4×0.0×0.4×+0.1×0.3×-0.1×
Debt-to-assets0.2×0.0×0.2×0.0×0.2×0.0×0.2×+0.1×0.2×-0.1×
Net debt / EBITDA1.2×-0.2×1.4×+0.5×-0.5×1.4×+0.5×0.9×-0.7×
Per Share
Book value per share$125.69+1.3%$124.11+0.3%$123.78+3.0%$120.20+3.8%$115.82+1.1%
Valuation
Market capitalization$26.91B+4.2%$25.82B+25.7%$20.54B+11.0%$18.51B-7.6%$20.03B-10.1%
Enterprise value$30.08B+2.1%$29.47B+26.7%$23.27B+4.1%$22.34B+0.2%$22.3B-16.2%
Price / earnings18.9×-0.3×19.2×+6.5×12.8×+0.7×12.1×-1.4×13.5×-0.1×
Price / sales2.7×+0.1×2.6×+0.6×+0.2×1.9×-0.2×-0.3×
Price / book1.4×0.0×1.4×+0.3×1.1×+0.1×-0.1×1.2×-0.2×
EV / EBITDA11.2×-0.2×11.4×+3.3×8.1×-0.1×8.2×-0.3×8.4×-1.2×
EV / sales0.0×+0.7×2.3×+0.1×2.2×0.0×2.3×-0.5×
Free cash flow yield9%+1.1pp7.9%-3.3pp11.2%+0.5pp10.7%-1.5pp12.2%0.0pp
Earnings yield5.3%+0.1pp5.2%-2.6pp7.8%-0.4pp8.3%+0.9pp7.4%+0.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Biogen's profit margins?
Biogen (BIIB) runs a 75.5% gross margin and a 22.9% operating margin, with a 14.3% net margin.
Where do Biogen's ratios come from?
Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.